Overview
- Tilray shares jumped about 27% on Dec. 16 to close at $13.94, with trading volume roughly 721% above average as the stock logged a gain of more than 60% over five sessions.
- The rally followed President Trump’s statement that he is very strongly considering an executive order to move marijuana to Schedule III.
- Tilray CEO Irwin Simon said he is a lot more optimistic about the cannabis sector following the president’s comments.
- Recent results showed improving fundamentals at Tilray, including record fiscal Q1 2026 revenue of $210 million, a return to $1.5 million in net income, $7.7 million in debt reduction, $265 million in cash, and $22.5 million raised via an at-the-market program that helped restore Nasdaq compliance.
- Reclassification remains unfinalized, and analysts continue to flag industry headwinds such as thin margins, high inventories, illicit-market competition, and permitting or quota delays in markets like Portugal and Germany.